Updates are available Correction dated 2024-04-18
Click to view Correction: https://doi.org/10.1038/s41598-024-59807-9
-
Authors
Guzik, Mateusz
Iwanek, Gracjan
Fudim, Marat
Zymliński, Robert
Marciniak, Dominik
Ponikowski, Piotr
Biegus, Jan
-
Funding
Funding for this research was provided by:
Institute of Heart Diseases, Wroclaw Medical University, Poland. (SUBZ.A460.23.055)
Institute of Heart Diseases, Wroclaw Medical University, Poland. (SUBZ.A460.23.055)
Institute of Heart Diseases, Wroclaw Medical University, Poland. (SUBZ.A460.23.055)
Institute of Heart Diseases, Wroclaw Medical University, Poland. (SUBZ.A460.23.055)
Institute of Heart Diseases, Wroclaw Medical University, Poland. (SUBZ.A460.23.055)
Institute of Heart Diseases, Wroclaw Medical University, Poland. (SUBZ.A460.23.055)
- License Information
-
More Information
Article History
Received: 26 April 2023
Accepted: 9 January 2024
First Online: 17 January 2024
Change Date: 18 April 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-59807-9
Competing interests
: M.F. was supported by the National Heart, Lung, and Blood Institute (NHLBI) (K23HL151744), the American Heart Association (20IPA35310955), Doris Duke, Bayer, Bodyport, and Verily. He receives consulting fees from Abbott, Alio Health, Alleviant, Audicor, AxonTherapies, Bayer, Bodyguide, Bodyport, Boston Scientific, Cadence, Coridea, CVRx, Daxor, Deerfield Catalyst, Edwards LifeSciences, EKO, Feldschuh Foundation, Fire1, Gradient, Impulse Dynamics, Intershunt, Medtronic, NIMedical, NXT Biomedical, Pharmacosmos, PreHealth, ReCor, Shifamed, Splendo, Sumacor, SyMap, Verily, Vironix, Viscardia, Zoll. P.P. reports personal fees from Boehringer Ingelheim, AstraZeneca, Servier, Bristol Myers Squibb, Amgen, Novartis, Merck, Pfizer, Berlin Chemie, and grants and personal fees from Vifor Pharma. M.G., G.I., R.Z., D.M., J.B. have no competing interests.
